Zhengye Biotechnology Holding (ZYBT) Non-Current Deferred Tax Liability (2025)
Zhengye Biotechnology Holding (ZYBT) reported Non-Current Deferred Tax Liability of $14663.2 for Q4 2025.
Zhengye Biotechnology Holding (ZYBT) Non-Current Deferred Tax Liability (2025) Analysis & Trends
Zhengye Biotechnology Holding (ZYBT) has 1 years of Non-Current Deferred Tax Liability data on file, last reported at $14663.2 in Q4 2025.
- Non-Current Deferred Tax Liability for Q4 2025 came in at $14663.2, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $14663.2 (changed N/A YoY), and the FY2025 annual result was $15000.0, changed N/A from the prior year.
- Non-Current Deferred Tax Liability steadied at $14663.2 in Q4 2025 per ZYBT's latest filing.
- Over five years, Non-Current Deferred Tax Liability peaked at $14663.2 in Q4 2025 and troughed at $14663.2 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Zhengye Biotechnology Holding | 5.49 Mn | 6.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 14,663.23 |
| Dec 31, 2025 | 14,663.23 |